AR012998A1 - Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente. - Google Patents
Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.Info
- Publication number
- AR012998A1 AR012998A1 ARP980102884A ARP980102884A AR012998A1 AR 012998 A1 AR012998 A1 AR 012998A1 AR P980102884 A ARP980102884 A AR P980102884A AR P980102884 A ARP980102884 A AR P980102884A AR 012998 A1 AR012998 A1 AR 012998A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- sensitizer
- preparation
- pharmaceutical composition
- insulin sensitizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Uso de un sensibilizador a insulina y de un agente antihiperglucémico para la preparacion de un medicamento util para el tratamiento y/o porfilaxia dediabetes mellitus, condiciones asociadas con la diabetes mellitus y ciertas complicaciones del a misma, en un mamífero, que comprende una cantidad eficazno toxica y farmacéuticamente aceptable de un sensibilizador a insulina y de un agente antihiperglucémico del tipo de biguanida, a un mamífero que necesita deello, y a una composicionfarmacé utica que comprende un sensibilizador a insulina y un agente antihiperglucémico del tipo de biguanida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9712857.3A GB9712857D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
GBGB9806706.9A GB9806706D0 (en) | 1998-03-27 | 1998-03-27 | Novel method |
Publications (1)
Publication Number | Publication Date |
---|---|
AR012998A1 true AR012998A1 (es) | 2000-11-22 |
Family
ID=26311745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102884A AR012998A1 (es) | 1997-06-18 | 1998-06-17 | Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente. |
ARP980102880A AR012995A1 (es) | 1997-06-18 | 1998-06-17 | Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102880A AR012995A1 (es) | 1997-06-18 | 1998-06-17 | Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos. |
Country Status (39)
Country | Link |
---|---|
US (3) | US20060100247A1 (es) |
EP (2) | EP0996444B1 (es) |
JP (1) | JP2002504137A (es) |
KR (2) | KR100666591B1 (es) |
CN (2) | CN1114404C (es) |
AP (1) | AP1279A (es) |
AR (2) | AR012998A1 (es) |
AT (1) | ATE355840T1 (es) |
AU (1) | AU8539398A (es) |
BG (2) | BG109398A (es) |
BR (1) | BR9810172A (es) |
CA (1) | CA2294582C (es) |
CY (2) | CY1107643T1 (es) |
CZ (1) | CZ298469B6 (es) |
DE (2) | DE122007000054I1 (es) |
DK (1) | DK0996444T3 (es) |
DZ (1) | DZ2520A1 (es) |
EA (1) | EA003144B1 (es) |
ES (1) | ES2284212T3 (es) |
HK (1) | HK1028193A1 (es) |
ID (1) | ID23372A (es) |
IL (3) | IL133142A0 (es) |
IN (1) | IN189722B (es) |
LU (1) | LU91356I2 (es) |
MA (1) | MA26512A1 (es) |
MY (1) | MY129897A (es) |
NL (1) | NL300288I2 (es) |
NO (4) | NO324993B1 (es) |
NZ (1) | NZ501260A (es) |
OA (1) | OA11516A (es) |
PE (1) | PE83199A1 (es) |
PL (2) | PL195140B1 (es) |
PT (1) | PT996444E (es) |
SI (1) | SI0996444T1 (es) |
SK (1) | SK286029B6 (es) |
TR (1) | TR199903057T2 (es) |
TW (1) | TW565449B (es) |
UY (1) | UY25049A1 (es) |
WO (1) | WO1998057634A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO318765B1 (no) * | 1995-07-03 | 2005-05-02 | Sankyo Co | Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner. |
GB9712857D0 (en) * | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
DK0974356T3 (da) * | 1998-07-15 | 2003-10-27 | Merck Sante Sas | Tabletter omfattende en kombination af metformin og glibenclamid |
WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
CO5170424A1 (es) | 1999-04-23 | 2002-06-27 | Smithkline Beecham Plc | Nuevosa compuestos antidiabeticos |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
NZ518278A (en) | 1999-11-03 | 2004-10-29 | Bristol Myers Squibb Co | Pharmaceutical composition comprising a combination of metformin and glibenclamide |
AU1403501A (en) * | 1999-11-16 | 2001-05-30 | Smithkline Beecham Plc | Novel composition and use |
AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
ES2290130T3 (es) * | 2000-05-01 | 2008-02-16 | Aeropharm Technology, Llc | Formulacion de nucleo. |
FR2812547B1 (fr) * | 2000-08-04 | 2002-10-31 | Lipha | Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete |
PL362687A1 (en) | 2001-01-12 | 2004-11-02 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
FR2838968A1 (fr) * | 2002-04-30 | 2003-10-31 | Lipha | Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete |
US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
ES2529180T3 (es) * | 2002-09-20 | 2015-02-17 | Andrx Labs Llc | Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona |
UA80991C2 (en) * | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US7976853B2 (en) | 2003-01-29 | 2011-07-12 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
CN1327840C (zh) * | 2004-06-08 | 2007-07-25 | 天津药物研究院 | 一种药物组合物及其在制备用于治疗糖尿病中的应用 |
JPWO2006011397A1 (ja) * | 2004-07-27 | 2008-05-01 | 興和株式会社 | 糖尿病の予防または治療のための薬剤 |
WO2006086727A2 (en) * | 2005-02-09 | 2006-08-17 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
BRPI0613447A2 (pt) * | 2005-07-12 | 2016-11-16 | Daiichi Sankyo Co Ltd | composição farmacêutica, usos de um agonista de ppargama e de um agente biguanida, e, kit para evitar ocorrência de efeitos colaterais adversos devido à ação de um agente biguanida no tratamento do diabetes |
US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
EP1854794A1 (en) * | 2006-05-09 | 2007-11-14 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
CN101069745B (zh) * | 2006-05-12 | 2010-07-21 | 北京华安佛医药研究中心有限公司 | 治疗2型糖尿病的药物组合物 |
US7919410B2 (en) * | 2007-03-14 | 2011-04-05 | Aptina Imaging Corporation | Packaging methods for imager devices |
CN102137836B (zh) * | 2008-07-28 | 2015-08-26 | 赛丹思科大学 | 用于治疗代谢疾病的化合物 |
DE102009053562A1 (de) | 2009-11-18 | 2011-05-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
KR20140035331A (ko) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 화학감각 수용체 리간드-기반 요법 |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
WO2013103919A2 (en) | 2012-01-06 | 2013-07-11 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
KR102035879B1 (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
JPH06779B2 (ja) * | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
DE3856378T2 (de) * | 1987-09-04 | 2000-05-11 | Beecham Group P.L.C., Brentford | Substituierte Thiazolidindionderivate |
US4895862A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5068342A (en) * | 1989-10-27 | 1991-11-26 | American Home Products Corporation | 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
WO1991007107A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
JPH04210683A (ja) * | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
ES2101866T3 (es) * | 1991-08-26 | 1997-07-16 | Upjohn Co | Producto alimentario liquido que contiene acido 3-guanidinopropionico. |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
ES2161291T3 (es) * | 1995-06-06 | 2001-12-01 | Pfizer | N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa. |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
JPH09270635A (ja) * | 1996-04-01 | 1997-10-14 | Honda Motor Co Ltd | 平面アンテナモジュール |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
US20020177612A1 (en) * | 1997-06-05 | 2002-11-28 | Smithkline Beecham P.I.C. | Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
CA2312990C (en) * | 1997-12-08 | 2008-04-29 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
EP1555845A1 (de) * | 2004-01-15 | 2005-07-20 | Siemens Aktiengesellschaft | Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems |
-
1998
- 1998-06-15 PT PT98936364T patent/PT996444E/pt unknown
- 1998-06-15 TR TR1999/03057T patent/TR199903057T2/xx unknown
- 1998-06-15 ID IDW991629A patent/ID23372A/id unknown
- 1998-06-15 KR KR1019997011865A patent/KR100666591B1/ko not_active IP Right Cessation
- 1998-06-15 EP EP98936364A patent/EP0996444B1/en not_active Revoked
- 1998-06-15 DE DE200712000054 patent/DE122007000054I1/de active Pending
- 1998-06-15 PL PL98337362A patent/PL195140B1/pl not_active IP Right Cessation
- 1998-06-15 SK SK1792-99A patent/SK286029B6/sk not_active IP Right Cessation
- 1998-06-15 CN CN98806224A patent/CN1114404C/zh not_active Expired - Lifetime
- 1998-06-15 EP EP07103607A patent/EP1787646A3/en not_active Withdrawn
- 1998-06-15 IL IL13314298A patent/IL133142A0/xx unknown
- 1998-06-15 AP APAP/P/1999/001719A patent/AP1279A/en active
- 1998-06-15 ES ES98936364T patent/ES2284212T3/es not_active Expired - Lifetime
- 1998-06-15 BR BR9810172-2A patent/BR9810172A/pt not_active Application Discontinuation
- 1998-06-15 CZ CZ0457899A patent/CZ298469B6/cs not_active IP Right Cessation
- 1998-06-15 KR KR1020067019737A patent/KR20060105005A/ko not_active Application Discontinuation
- 1998-06-15 AU AU85393/98A patent/AU8539398A/en not_active Abandoned
- 1998-06-15 SI SI9830883T patent/SI0996444T1/sl unknown
- 1998-06-15 DE DE69837261T patent/DE69837261T2/de not_active Expired - Lifetime
- 1998-06-15 EA EA200000041A patent/EA003144B1/ru not_active IP Right Cessation
- 1998-06-15 PL PL98377980A patent/PL195136B1/pl not_active IP Right Cessation
- 1998-06-15 DK DK98936364T patent/DK0996444T3/da active
- 1998-06-15 WO PCT/EP1998/003690 patent/WO1998057634A1/en active IP Right Grant
- 1998-06-15 CA CA002294582A patent/CA2294582C/en not_active Expired - Fee Related
- 1998-06-15 CN CNB021561281A patent/CN1230171C/zh not_active Expired - Fee Related
- 1998-06-15 JP JP50375599A patent/JP2002504137A/ja active Pending
- 1998-06-15 AT AT98936364T patent/ATE355840T1/de active
- 1998-06-15 NZ NZ501260A patent/NZ501260A/xx unknown
- 1998-06-17 AR ARP980102884A patent/AR012998A1/es unknown
- 1998-06-17 DZ DZ980130A patent/DZ2520A1/xx active
- 1998-06-17 AR ARP980102880A patent/AR012995A1/es unknown
- 1998-06-17 TW TW087109617A patent/TW565449B/zh not_active IP Right Cessation
- 1998-06-17 MA MA25123A patent/MA26512A1/fr unknown
- 1998-06-17 MY MYPI98002711A patent/MY129897A/en unknown
- 1998-06-18 IN IN1694DE1998 patent/IN189722B/en unknown
- 1998-06-18 UY UY25049A patent/UY25049A1/es not_active Application Discontinuation
- 1998-06-18 PE PE1998000534A patent/PE83199A1/es not_active Application Discontinuation
-
1999
- 1999-11-25 IL IL133142A patent/IL133142A/en unknown
- 1999-12-17 OA OA9900294A patent/OA11516A/en unknown
- 1999-12-17 NO NO19996266A patent/NO324993B1/no not_active IP Right Cessation
-
2000
- 2000-01-06 BG BG109398A patent/BG109398A/bg unknown
- 2000-01-06 BG BG10406A patent/BG64818B1/bg unknown
- 2000-10-25 HK HK00106802A patent/HK1028193A1/xx not_active IP Right Cessation
-
2005
- 2005-12-14 US US11/302,999 patent/US20060100247A1/en not_active Abandoned
-
2006
- 2006-02-09 IL IL173650A patent/IL173650A0/en unknown
- 2006-06-28 NO NO20063000A patent/NO326958B1/no not_active IP Right Cessation
- 2006-09-01 US US11/469,530 patent/US20070004780A1/en not_active Abandoned
-
2007
- 2007-05-31 CY CY20071100727T patent/CY1107643T1/el unknown
- 2007-08-23 CY CY2007018C patent/CY2007018I1/el unknown
- 2007-08-29 LU LU91356C patent/LU91356I2/fr unknown
- 2007-08-31 NL NL300288C patent/NL300288I2/nl unknown
- 2007-12-10 US US11/953,133 patent/US20080090881A1/en not_active Abandoned
-
2008
- 2008-04-03 NO NO2008003C patent/NO2008003I2/no unknown
-
2009
- 2009-02-24 NO NO20090846A patent/NO20090846L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR012998A1 (es) | Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente. | |
UY25799A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético. | |
ES2150889T1 (es) | Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii. | |
ES2062392T3 (es) | Medicamentos que comprenden salmeterol y fluticasona. | |
BR9809988A (pt) | Mecanismo de regulagem de dose e uma seringa de injeção que tem um mecanismo de regulagem de dose como esse | |
GEP20053539B (en) | Antidiabetic Formulation | |
ES488168A0 (es) | Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada. | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
BR0108584A (pt) | Formulações contendo um fármaco anticolinérgico para o tratamento da broncopneumopatia crÈnica obtrutiva | |
CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). | |
HUP0101293A2 (hu) | AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása | |
ATE281171T1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
BR9810445A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e diguanida | |
UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
ES2152272T3 (es) | Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica. | |
ES2142388T3 (es) | Agente anti-diabetico. | |
SK42395A3 (en) | Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof | |
AR014881A1 (es) | Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprendedicho sensibilizador y dicho agente | |
AR012997A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene. | |
AR012996A1 (es) | Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador. | |
ES2171459T3 (es) | Polvo para administracion nasal de farmaco peptidico o proteinaceo. | |
AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
AR019724A2 (es) | Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas | |
FI951683A (fi) | Yhdisteiden, joilla on antiglukokortikoidiaktiivisuus, käytt¦ sellaisten lääkkeiden valmistamiseksi, jotka on tarkoitettu huumausaineiden tai huumausaineseosten spontaaniin tai laukaistuun vieroitusoireyhtymäänliittyvien oireiden estämiseen tai hoitoon, ja niitä sisältäviä |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |